KBI Biopharma and Selexis SA Appoint JD Mowery as Executive Director

2023-04-17 19:06:29

KBI Biopharma, Inc. (KBI) and Selexis SA, both companies of JSR Life Sciences, today announced the appointment of JD Mowery as Chief Executive Officer. Widely respected as an innovative leader in biotechnology with a nearly 25-year track record of success inspiring peers and building organizations, JD will lead KBI and Selexis into the next chapter of becoming a leader in the next generation of development and contract manufacturing organizations that are emerging.

news-body-cta">This press release includes multimedia. See the full statement here:

J.D. Mowery, KBI Biopharma and Selexis SA Chief Executive Officer (Photo: Business Wire)

“Throughout decades of service, JD has dedicated his career to meaningful work with a clear focus on patient impact through the launch of new therapies and providing world-class service to manufacturing and development partners,” said Tim Lowery, President of JSR Life Sciences. “As we enter a phase of critical growth, JD will play a critical role in leading KBI and Selexis, as well as empowering our international teams to succeed through service leadership. We are confident that their commitment to our long-term impact will drive us to greater success.”

JD will leverage his extensive experience in the global biopharmaceutical industry in operations, manufacturing, technology transfer, facility construction, business development, employee growth and investor relations. Previously, having worked on both sides of the industry with innovators such as Genentech, Celgene, Juno and, more recently, Treadwell Therapeutics, as well as development and contract manufacturing organizations, Lonza and AGC Biologics, he gained experience in a variety of modalities, including small molecules , biologics and cells, and gene therapy.

“It is an honor to join KBI and Selexis at the perfect tipping point where we can leverage the collective knowledge, scientific expertise and resources of the entire JSR ecosystem,” said JD “I am fortunate to work with an incredibly talented team and, energized by Our current and future partnerships will see us positively impact the industry as an example of a true next-generation development and contract manufacturing organization.”

JD concluded, “I am truly looking forward to leading KBI and Selexis with a relentless focus on realizing our full potential for our people, partners and, most importantly, the patients around the world that we serve together.”

JD will work closely with JSR leadership to ensure continued alignment of goals and continue to identify strategic opportunities for growth within the broader JSR ecosystem.

About KBI Biopharma, Inc.

KBI Biopharma, Inc., a JSR Life Sciences company, is a worldwide contract development and manufacturing organization (CDMO) that provides fully integrated, accelerated drug development, biologics manufacturing and expertise services to life science companies . With each of its more than 500 customers in partnership, KBI works closely to quickly customize and accelerate drug development programs. Built on a foundation of world-class analytical capabilities and extensive scientific and technical experience, KBI offers robust process development as well as clinical and commercial cGMP manufacturing services for cell, microbial and mammalian therapy programs. Renowned for quality manufacturing, KBI helps partners bring drug candidates to market. KBI serves its international partners from eight locations in Europe and the US. More information is available at www.kbibiopharma.com.

About Selexis SA

Selexis SA, a JSR Life Sciences company, is a world leader in developing mammalian cell lines with the best modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative drugs and vaccines. Our international partners have used Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development, as well as in the manufacture of ten commercial products. As part of a comprehensive drug development process, Selexis technologies shorten development timelines and reduce manufacturing risk. More information is available at www.selexis.com.

The original language text of this announcement is the official authorized version. Translations are provided as a convenience only and must refer to the original language text, which is the only version of the text that is legally binding.